Back to top
more

ANI Pharmaceuticals (ANIP)

(Delayed Data from NSDQ)

$61.43 USD

61.43
153,427

-2.34 (-3.67%)

Updated May 17, 2024 04:00 PM ET

After-Market: $61.42 -0.01 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Amylyx (AMLX) Withdraws ALS Drug, Cuts Workforce by 70%

by Zacks Equity Research

Amylyx (AMLX) makes a formal decision to remove its amyotrophic lateral sclerosis drug from the U.S. and Canadian markets. The company is expected to reduce its workforce by 70%. Its shares are trading up on the news.

Amarin (AMRN) Up 7% on Intellectual Property Wins in Europe

by Zacks Equity Research

Amarin (AMRN) secures a new patent for Vazkepa in Europe, which extends its exclusivity for eight more years. It achieves success in defending another patent on the drug against third parties.

Kintara (KTRA) Stock Soars on Merger Agreement With TuHURA

by Zacks Equity Research

Kintara (KTRA) inks a definitive merger agreement with TuHURA for an all-stock transaction. It is expected to close in the third quarter of 2024. The stock surges 63.4%.

Verve (VERV) Pauses Enrollment in Cholesterol Study, Stock Falls

by Zacks Equity Research

Verve (VERV) stops enrollment in the phase Ib study of gene therapy candidate VERVE-10 to reduce disease-driving low-density lipoprotein cholesterol due to safety issues. Stock plunges on the news.

Vanda (VNDA) Up on FDA Nod for Fanapt in Bipolar I Disorder

by Zacks Equity Research

Vanda (VNDA) announces the FDA's approval of Fanapt for the acute treatment of bipolar I disorder in adults. The stock rises 30.4%.

EMA Accepts Rocket (RCKT) Gene Therapy Filing for Fanconi Anemia

by Zacks Equity Research

The EMA accepts Rocket's (RCKT) regulatory submission seeking approval for RP-L102, a gene therapy for a rare genetic disorder called fanconi anemia that affects the bone marrow.

Bristol Myers (BMY) Wins EC Nod for Reblozyl Label Expansion

by Zacks Equity Research

Bristol Myers (BMY) receives European Commission's approval for a label expansion of Reblozyl (luspatercept) for another indication.

ANI Pharmaceuticals (ANIP) Dips More Than Broader Market: What You Should Know

by Zacks Equity Research

ANI Pharmaceuticals (ANIP) closed at $66.72 in the latest trading session, marking a -1.69% move from the prior day.

Disc Medicine (IRON) Down on Mixed Results From AURORA Study

by Zacks Equity Research

Disc Medicine's (IRON) shares lose after a phase II study of bitopertin in patients with erythropoietic protoporphyria does not achieve the key secondary endpoint.

Avalo Therapeutics (AVTX) Surges 270% in a Week: Here's Why

by Zacks Equity Research

Avalo (AVTX) surges on adding a new pipeline drug, which has its origins at Eli Lilly. Alongside the acquisition, it also secured funding to continue operations beyond 2027.

Vertex (VRTX) Moves Kidney Disease Drug to Phase 3 Development

by Zacks Equity Research

Vertex (VRTX) advances inaxaplin to late-stage development. It will evaluate the drug in lower age groups and will enroll patients aged 10 years and older with APOL1-mediated kidney disease.

Solid Biosciences (SLDB) Falls Despite FDA Rare Tag for DMD Drug

by Zacks Equity Research

Solid Biosciences' (SLDB) novel gene-therapy candidate, SGT-003, gets FDA's Rare Pediatric Disease Designation for the treatment of Duchenne muscular dystrophy.

Axsome (AXSM) Begins Solriamfetol Binge Eating Phase III Study

by Zacks Equity Research

Axsome's (AXSM) phase III ENGAGE study is set to evaluate the efficacy and safety of solriamfetol for the treatment of binge eating disorder in adults.

Kodiak (KOD) Stock Falls on Q4 Earnings Miss, Pipeline in Focus

by Zacks Equity Research

Kodiak (KOD) reports a wider-than-expected loss for fourth-quarter 2023. The company provides updates regarding its pipeline development plans.

Moderna (MRNA) Posts Pipeline Progress, Secures Blackstone Funding

by Zacks Equity Research

Moderna (MRNA) posts data on three experimental vaccines and intends to advance them to late-stage studies. It also secures $750 million in funding from Blackstone to advance its influenza program.

ANI Pharmaceuticals (ANIP) Rises Yet Lags Behind Market: Some Facts Worth Knowing

by Zacks Equity Research

ANI Pharmaceuticals (ANIP) concluded the recent trading session at $69.69, signifying a +0.2% move from its prior day's close.

Praxis (PRAX) Surges on Positive Epilepsy Study Results

by Zacks Equity Research

Praxis (PRAX) reports strong response rates across both study arms in a phase IIa proof of concept study for epilepsy patients with PPR.

Axsome's (AXSM) Narcolepsy Drug Study Meets Primary Goal

by Zacks Equity Research

Data from a late-stage study shows that a five-week treatment with Axsome's (AXSM) experimental narcolepsy drug reduced weekly cataplexy attacks by 83%, compared to 66% for placebo.

CHMP to Delay Nod on Biogen (BIIB), Eisai's Alzheimer's Drug

by Zacks Equity Research

Per Biogen (BIIB)/Eisai, the delay in CHMP recommendation for lecanemab is entirely related to procedural reasons at the EMA and is not related to the companies' regulatory filing.

Regeneron's (REGN) Lymphoma Candidate Rejected by the FDA

by Zacks Equity Research

Regeneron's (REGN) efforts to expand its oncology portfolio get a hit as the FDA refuses to approve the lymphoma drug odronextamab.

ANI Pharmaceuticals, Inc. (ANIP) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

ANI (ANIP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Lisata's (LSTA) LSTA1 Gets FDA's RPDD Tag for Osteosarcoma

by Zacks Equity Research

Lisata's (LSTA) lead investigational product candidate, LSTA1, gets Rare Pediatric Disease Designation for treating osteosarcoma. Stock rises.

Novo Nordisk (NVO) Gets Positive CHMP Opinion for Insulin Icodec

by Zacks Equity Research

Novo Nordisk (NVO) receives a positive opinion from the CHMP for once-weekly basal insulin icodec for the treatment of diabetes in adults.

Merck's (MRK) Keytruda-Lynparza Combo Fails 2nd Lung Cancer Study

by Zacks Equity Research

Merck's attempt to use the Keytruda-Lynparza combination in certain non-small cell lung cancer patients has come up short with a second pivotal study failure.

ANI Pharmaceuticals (ANIP) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

ANI Pharmaceuticals (ANIP) closed at $69.32 in the latest trading session, marking a +1.7% move from the prior day.